RNS Number: 6998V JPMorgan UK Small Cap Grwth&Inc PLC 03 February 2025

## LONDON STOCK EXCHANGE ANNOUNCEMENT

## JPMORGAN UK SMALL CAP GROWTH & INCOME PLC

(the 'Company')

## **Closed Period Notification**

## Legal Entity Identifier: 549300PXALXKUMU9JM18 Information disclosed in accordance with MAR Article 19, paragraph 11

The Company announces that it is satisfied that all inside information which the Directors and the Company may have in the period leading up to the announcement of its half year results for the six months ended 31st January 2025 has previously been, and will continue to be, notified to the London Stock Exchange (LSE) via a regulatory information service. Therefore, the Company is not prohibited from dealing in its own securities.

The mandatory closed period under MAR will commence on 11th February 2025 and will last until the half year results in respect of the six months ended 31st January 2025 are published, which is expected on or around 24th March 2025.

If in the period leading up to the announcement of the half yearesults the Directors of the Company come into the possession of any inside information, this will be notified to the London Stock Exchange without delay and before any such transactions are undertaken.

JPMorgan Funds Limited, Company Secretary 3rd February 2025

For further information, please contact:

Lucy Dina JPMorgan Funds Limited 0800 20 40 20 (or +44 1268 44 44 70)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:rns@lseg.com">rns@lseg.com</a> or visit <a href="mailto:www.ms.com">www.ms.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.